Immunocore Holdings plc (IMCR)
Immunocore Holdings plc (IMCR) from its SEC filings: 2025 revenue $400.0 million (+29% vs the year before), net margin -9%, free cash flow -$15.1 million. Insider trades, recent filings and a price chart. Free.
| Exchange | Nasdaq |
| Industry | Biological Products, (No Diagnostic Substances) |
| Revenue (2025) | $400.0 million |
| Revenue growth | +29% |
| Net income | -$35.5 million |
| Net margin | -8.9% |
| Free cash flow | -$15.1 million |
| Diluted EPS | $-0.71 |
| Latest quarter (Q2 2026 (calendar)) revenue vs a year earlier | +18% |
| Cash | $484.9 million |
| Long-term debt | $438.7 million |
| Share count, 1 year | +2% |
| Fundamentals check | Mixed fundamentals |
Source: SEC EDGAR company filings (XBRL), updated 2026-10-23. Education only, not financial advice.